Engage Bio
YC W22 ↗San Francisco, US · Founded 2021 · 10 employees · Acquired · 4 known investors
EngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
BiotechDigital HealthHealthtechSynthetic BiologyHealthcareTherapeuticsDrug discoveryin /engagebio/@ycombinatorycombinator.com ↗
Founders & leadership· Y Combinator alumni (W22)
WO
Will OlseninFounder
Investors · 4
In the news
- Lilly and Engage Bio tie the knot with $202M acquisition - BioSpacebiospace.com · 2026
- Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines - AOLaol.com · 2026
- Engage Bio - MBC BioLabsmbcbiolabs.com · 2024
- Granza Bio Raises $7M+ Seed Funding to Advance the Delivery of Cancer Treatment and Genetic Medicinesprnewswire.com · 2024